Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
AEON Biopharma (AEON) has shared an update.
AEON has halted its Phase 2 study and related open label extension study on ABP-450 for migraine treatment after the trials failed to meet primary endpoints, though some secondary goals were achieved. Patients will continue to be monitored for safety. This decision will help AEON save cash as it considers future strategic directions.
Find detailed analytics on AEON stock on TipRanks’ Stock Analysis page.
